top of page
Technoclone logo: Shedding Light on Von Willebrand Disease: Technoclone's Pioneering Diagnostic Solution with the help of Microfluidics Innovation Hub
Open Call Project
Shedding Light on Von Willebrand Disease

Technoclone's Pioneering Point-of-Care Solution

In the intricate realm of blood disorders, Von Willebrand Disease (VWD) stands out as a common yet often misunderstood condition. With Technoclone's groundbreaking initiative, the landscape of VWD diagnostics is poised for transformation, promising enhanced accuracy, speed, and accessibility in patient care. This exploration dives into the scientific complexities of VWD, the challenges in its diagnosis, and how Technoclone, with the support of the #MIHfamily, is paving the way for revolutionary diagnostics.

Understanding Von Willebrand Disease

Von Willebrand Disease is the most common hereditary bleeding disorder, affecting both males and females. It arises from a deficiency or dysfunction of the Von Willebrand Factor (VWF), a crucial protein in blood clotting. VWF is essential for platelet adhesion to blood vessel walls at injury sites and for binding to factor VIII, a vital component in the clotting cascade. Mutations in the VWF gene lead to decreased levels or impaired function of VWF, causing symptoms of VWD that can range from mild to severe bleeding episodes.

The Diagnostic Dilemma

Diagnosing VWD has traditionally been a complicated, time-consuming, and often costly process. It requires a series of blood tests to measure VWF levels and functionality, alongside other coagulation assessments. These complexities can delay diagnosis and treatment, negatively impacting patient outcomes and quality of life.

Technoclone's Innovative Approach

Technoclone is at the forefront of innovation in diagnostics, aiming to redefine the diagnosis of VWD through the power of microfluidics. Their approach seeks to condense the cumbersome diagnostic process into a rapid, cost-effective, and highly accurate test. By integrating ELISA tests into a microfluidic platform, Technoclone's solution not only streamlines VWD diagnosis but also makes it more accessible to patients worldwide.

Discover how Technoclone is transforming VWD diagnosis

Technoclone has approached MIH to transfer their Von Willebrand Factor assay to a rapid point-of-care platform.

Send us your inquiry today to join the forefront of point-of-care diagnostics!

Infographic of Von Wille Brandt pathway and blood coagulation - by technoclone.

Develop a microfluidic platform that integrates ELISA tests for comprehensive VWD diagnostics.
Simplify and accelerate the diagnostic process for VWD, making it more accessible and cost-effective.
Enhance the accuracy and reliability of VWD diagnosis, ensuring better patient outcomes.


Project Management and Communication: MIH oversees project coordination, ensuring efficient progress and development.
Assay Development and Multiplexing: GSB focuses on developing and optimizing the multiplex assay for VWD diagnostics.
Protein Printing and Coating: SCI specializes in printing and immobilizing the necessary proteins for the diagnostic assays.
Microfluidic Platform Development: GSB handles the development, prototyping, and optimization of the microfluidic components.


High sensitivity and specificity in detecting and quantifying VWF deficiencies and subtypes.
Rapid and reliable diagnostic process using microfluidic technology.

The Role of the #MIHfamily

  • Microfluidics Innovation Hub (MIH): Providing overall project management and coordination, supporting the development and implementation of the microfluidic platform.

  • Genspeed Biotech GmbH (GSB): Specialized in:

  • Assay Development: Managing material, printing, and immobilization of diagnostic assays.

  • MVP Batch Production: Producing prototype batches of the multiplex assay for initial testing.

  • Read Out Technology: Customizing reader software for the microfluidic system.

  • Project Management and Communication: Coordinating and overseeing all project activities, including planning, meetings, and monitoring.

  • Scienion AG (SCI): Focused on:

  • Protein Coating and Printing: Using the sciFLEXARRAYER system for printing and immobilizing capture probes, including collagen and rGp1b proteins.

  • Collagen Printing: Developing specific pulse parameters for piezoelectric-based printing of collagen solutions.

Partners Involved

Explore More

Stay updated as we continue to innovate and enhance diagnostic solutions for VWD with Technoclone's pioneering microfluidic platform. Explore how our collaborative efforts are making a significant impact in the field of blood disorder diagnostics.

Services and Technologies

Technoclone’s collaboration with MIH and its partners highlights the power of collective innovation in healthcare. Together, we are creating a groundbreaking diagnostic tool that promises to transform the landscape of VWD diagnostics.

This project has received funding from the European Union’s HORIZON 2020 research & innovation programme under grant agreement no. 862092.

bottom of page